PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck

Approximately 686,330 cases of head and neck cancer (including nasopharyngeal carcinoma) occurred worldwide in 2012 [1], and an estimated 48,330 new cases will occur in the United States in 2016 [2]. Ninety percent of these tumors were squamous cell carcinoma of the head and neck (SCCHN) [3]. Approximately 12% of SCCHN cases diagnosed present with distant metastases [4], and ⩾50% of patients with locally advanced disease develop incurable relapse [5]. Notably, recent evidence indicated human papillomavirus (HPV)-positive and HPV-negative SCCHN are clinically and biologically distinct in the primary disease setting [6,7].

from #ORL via xlomafota13 on Inoreader http://ift.tt/2b86wDk
via IFTTT